Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cullinan Therapeutics Inc (NQ: CGEM )

16.48 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cullinan Therapeutics Inc

< Previous 1 2 3 4 5 Next >
UnitedHealth Reports Upbeat Earnings, Joins Cullinan Oncology, Ericsson And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were mostly higher, with the Dow Jones index gaining over 100 points on Tuesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Cullinan Management Inc. (NASDAQ: CGEM) Records 52-Week High Tuesday Morning
Via Investor Brand Network
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Cullinan Oncology: Q4 Earnings Insights
Via Benzinga
Recap: Cullinan Oncology Q3 Earnings
Via Benzinga
Analyst Ratings for Cullinan Oncology
Via Benzinga
Analyst Ratings for Cullinan Oncology
Via Benzinga
Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
CGEM Stock Earnings: Cullinan Oncology Beats EPS for Q4 2023
CGEM stock results show that Cullinan Oncology beat analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
From Cullinan Oncology, Inc.
Via GlobeNewswire
Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for Novel MICA/B Antibody, CLN-619, for Relapsed/Refractory Multiple Myeloma
From Cullinan Oncology, Inc.
Via GlobeNewswire
Analyst Expectations for Cullinan Oncology's Future
Via Benzinga
Expert Ratings for Cullinan Oncology
Via Benzinga
4 Analysts Have This to Say About Cullinan Oncology
Via Benzinga
Cullinan Oncology to Participate in Upcoming Investor Conferences
From Cullinan Oncology, Inc.
Via GlobeNewswire
Why Super Micro Computer Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket
Shares of Super Micro Computer, Inc. (NASDAQ: SMCI) shares rose sharply in today’s pre-market trading as the company posted upbeat results for its second quarter. 
Via Benzinga
Cullinan Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Cullinan Oncology, Inc.
Via GlobeNewswire
Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines
From Cullinan Oncology, Inc.
Via GlobeNewswire
Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2023 Financial Results
From Cullinan Oncology, Inc.
Via GlobeNewswire
Cullinan Oncology to Present Data Demonstrating Progress Across Its Broad Immunotherapy-Pipeline at SITC 2023
From Cullinan Oncology, Inc.
Via GlobeNewswire
Cullinan Oncology to Participate in Upcoming Investor Conferences
From Cullinan Oncology, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For October 6, 2023
Via Benzinga
Cullinan Oncology to Participate in Upcoming Investor Conferences
From Cullinan Oncology, Inc.
Via GlobeNewswire
Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2023 Financial Results
From Cullinan Oncology, Inc.
Via GlobeNewswire
Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-978, a Novel CD19xCD3 T cell Engager, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
From Cullinan Oncology, Inc.
Via GlobeNewswire
Cullinan Oncology to Participate in Upcoming Investor Conferences
From Cullinan Oncology, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For June 15, 2023
Via Benzinga
Why Shares of Cullinan Oncology Jumped This Week
The company's presentation at a conference got the attention of analysts and investors. 
Via The Motley Fool
Cullinan Oncology to Present First Monotherapy Clinical Data for CLN-619, a Novel Anti-MICA/B Antibody, at ASCO 2023
From Cullinan Oncology, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.